Broker Regulation

The DOL's complaint against BCBSM, Inc., as well as the series of lawsuits against other TPAs and insurers, may redefine the landscape of fiduciary responsibilities and the role of TPAs in plan administration.

Industry observers said that drug companies are likely to continue to oppose the government's efforts to reduce prices.

Plan sponsors must evaluate their current PBM arrangements and decide whether they have a transparent arrangement that they trust or if there is a need to re-evaluate the PBM relationship.

With the price of GLP-1s reaching well over $1000 a month, local officials are warning that rising costs threaten to quickly drain government spending accounts.

Data privacy professionals are keeping an eye on the set of state laws primed to go into effect in 2024.

"I expect that they will be looking for opportunities to apply all of the elements of the guidelines in merger cases -- to some extent, they've already been doing that," said former FTC Chair William Kovacic.